Get the Stockscreener App
163.94
0.99%
1.61
After Hours:
164.98
1.04
+0.63%
Insmed Inc stock is traded at $163.94, with a volume of 1.46M.
It is up +0.99% in the last 24 hours and up +12.34% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$162.33
Open:
$163.22
24h Volume:
1.46M
Relative Volume:
0.58
Market Cap:
$34.65B
Revenue:
$398.11M
Net Income/Loss:
$-1.03B
P/E Ratio:
-28.75
EPS:
-5.7032
Net Cash Flow:
$-868.57M
1W Performance:
+3.58%
1M Performance:
+12.34%
6M Performance:
+139.08%
1Y Performance:
+119.88%
1-Day Range:
$162.08
$166.44
1-Week Range:
$156.87
$166.44
52-Week Range:
$60.40
$166.44
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
163.94 | 34.31B | 398.11M | -1.03B | -868.57M | -5.7032 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Can Insmed Incorporated stock maintain operating marginsJuly 2025 Reactions & High Accuracy Trade Signal Alerts - newser.com
How Insmed Incorporated stock reacts to Fed rate cutsMarket Movement Recap & High Accuracy Buy Signal Tips - newser.com
Is Insmed Incorporated trending in predictive chart modelsPortfolio Performance Report & High Return Trade Opportunity Guides - newser.com
Is a relief rally coming for Insmed Incorporated holders2025 Short Interest & Capital Efficiency Focused Ideas - newser.com
What indicators show strength in Insmed IncorporatedPortfolio Gains Summary & Real-Time Market Trend Scan - newser.com
How to build a custom watchlist for Insmed IncorporatedPortfolio Risk Summary & Short-Term Swing Trade Alerts - newser.com
Reversal indicators forming on Insmed Incorporated stockJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
How Insmed Incorporated (IM8N) stock performs during market turbulenceQuarterly Earnings Report & Safe Capital Growth Stock Tips - newser.com
Maryland State Retirement & Pension System Invests $873,000 in Insmed, Inc. $INSM - MarketBeat
Aberdeen Group plc Decreases Stock Position in Insmed, Inc. $INSM - MarketBeat
Oak Ridge Investments LLC Sells 7,757 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed Incorporated stock prediction for this weekEarnings Risk Summary & High Accuracy Buy Signal Tips - newser.com
Insmed, Inc. $INSM Holdings Raised by KLP Kapitalforvaltning AS - MarketBeat
What moving averages say about Insmed IncorporatedJuly 2025 Summary & Daily Stock Trend Reports - newser.com
How buyback programs support Insmed Incorporated (IM8N) stockMarket Activity Recap & Stepwise Entry and Exit Trade Signals - newser.com
Real time breakdown of Insmed Incorporated stock performanceJuly 2025 Market Mood & High Yield Stock Recommendations - newser.com
What does recent volatility data suggest for Insmed Incorporated2025 Price Targets & Reliable Breakout Stock Forecasts - newser.com
Insmed stock hits 52-week high at 164.04 USD - Investing.com India
Insmed stock hits 52-week high at 164.04 USD By Investing.com - Investing.com Australia
How to interpret RSI for Insmed Incorporated stock2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Insmed (NASDAQ:INSM) - MarketBeat
Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Insmed, Inc. Hits New 52-Week High of $160.62, Up 164% Yearly - Markets Mojo
Insmed, Inc. Hits New 52-Week High of $162.44, Up 171% Year-Over-Year - Markets Mojo
Pulmonary Arterial Hypertension Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma - The Globe and Mail
This ‘Strong Buy’ Stock Is Trading at New 20-Year Highs - MSN
This ‘Strong Buy’ Stock Is Trading At New 20-Year Highs - Barchart.com
RBC Lifts Price Target on Insmed to $139 From $138, Keeps Outperform Rating - MarketScreener
Insmed (NASDAQ:INSM) Sets New 12-Month HighShould You Buy? - MarketBeat
Insmed, Inc. Hits New 52-Week High of $158.19, Up 162% - Markets Mojo
Is Insmed Incorporated a good long term investmentMorning Star Patterns & Free Popular Stock Picks Selection - earlytimes.in
111 Capital Makes New Investment in Insmed, Inc. $INSM - MarketBeat
Chung Wu Investment Group LLC Takes $173,000 Position in Insmed, Inc. $INSM - MarketBeat
Is Insmed Incorporated (IM8N) stock bottoming after sell offPortfolio Gains Summary & Daily Chart Pattern Signals - newser.com
How Analysts Are Rethinking Insmed After Brinsupri’s Approval and New Revenue Projections - Yahoo Finance
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $102 to $124 - 富途牛牛
Goldman Sachs Maintains Insmed (INSM) Buy Recommendation - Nasdaq
Goldman Sachs Raises Insmed (INSM) Price Target to $196 | INSM S - GuruFocus
Insmed (NASDAQ:INSM) Price Target Raised to $196.00 at The Goldman Sachs Group - MarketBeat
Goldman Sachs Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $196 - 富途牛牛
GAMMA Investing LLC Cuts Stock Holdings in Insmed, Inc. $INSM - Defense World
Insmed (NASDAQ:INSM) Given New $193.00 Price Target at TD Cowen - Defense World
Insmed (NASDAQ:INSM) Reaches New 12-Month High on Analyst Upgrade - Defense World
Insmed stock hits 52-week high at 149.2 USD By Investing.com - Investing.com Nigeria
Insmed (NASDAQ:INSM) Sets New 1-Year High After Analyst Upgrade - MarketBeat
Insmed stock hits 52-week high at 149.2 USD - Investing.com
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schaeffer Orlov S Nicole | Chief People Strategy Officer |
Sep 12 '25 |
Sale |
145.45 |
76,520 |
11,129,927 |
36,461 |
| SHAROKY MELVIN MD | Director |
Sep 12 '25 |
Sale |
145.39 |
10,000 |
1,453,900 |
262,675 |
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):